Macquarie to sell its 95 million shares in Oceania Healthcare

Macquarie group

Macquarie Group (ASX: MQG) has gone on selling down some of its stakes in New Zealand based aged care service provider, Oceania Healthcare.

As per the Oceania Healthcare’s disclosure to New Zealand Exchange, Macquarie Group has been found selling down 95 million shares of Oceania Healthcare. The group holds total of 57.2% stakes in Oceania Healthcare out of which the group intends to offload 15.6% of its stakes.

That means Macquarie would be left with approximately 42% of interest in the dual-listed aged care company. But smaller stakes mean little control. On the completion of this sell down, Macquarie may have to sacrifice its spot on board.  

The reports revealed that Macquarie New Zealand has entered into a Block Trade Agreement with Oceania Healthcare Holdings Limited (OHHL) to sell 95 million ordinary shares in Oceania. As per the terms of agreement, Deutsche Craigs Limited and Craigs Investment Partners Limited and First NZ Capital Group Limited were appointed to manage and underwrite the sale of 95,000,000 ordinary shares in Oceania held by OHHL.

It’s been heard that brokers have set a floor price of $NZ1.08. This represents a discount of  5.3% to the last close. The last traded price of NZX listed Oceania Healthcare Limited was $NZ1.140.

On the news of selling its stake in Oceania Healthcare, Macquarie Group’s stock dropped 0.631% to $127.560 as at 5 September 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report